EA201800229A1 - METHOD FOR PRODUCING PEMETREXEDA DISATRIUM 2,5-HYDRATE AND PHARMACEUTICAL COMPOSITION CONTAINING PEMETREXEDA DISATRIUM 2,5-HYDRATE - Google Patents

METHOD FOR PRODUCING PEMETREXEDA DISATRIUM 2,5-HYDRATE AND PHARMACEUTICAL COMPOSITION CONTAINING PEMETREXEDA DISATRIUM 2,5-HYDRATE

Info

Publication number
EA201800229A1
EA201800229A1 EA201800229A EA201800229A EA201800229A1 EA 201800229 A1 EA201800229 A1 EA 201800229A1 EA 201800229 A EA201800229 A EA 201800229A EA 201800229 A EA201800229 A EA 201800229A EA 201800229 A1 EA201800229 A1 EA 201800229A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydrate
pemetrexeda
disatrium
pharmaceutical composition
producing
Prior art date
Application number
EA201800229A
Other languages
Russian (ru)
Other versions
EA038700B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to EA201800229A priority Critical patent/EA038700B1/en
Publication of EA201800229A1 publication Critical patent/EA201800229A1/en
Publication of EA038700B1 publication Critical patent/EA038700B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mechanical Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к способу получения фармацевтической композиции, содержащей пеметрексед динатрий 2,5-гидрат в качестве активного ингредиента, в виде лиофилизированного порошка для приготовления раствора для инъекций. Предлагаемый способ обеспечивает получение фармацевтической композиции с высокой стабильностью и низкой загрузкой примесей.The invention relates to a method for producing a pharmaceutical composition containing pemetrexed disodium 2,5-hydrate as an active ingredient, in the form of a lyophilized powder for the preparation of an injection solution. The proposed method provides a pharmaceutical composition with high stability and low loading of impurities.

EA201800229A 2018-04-26 2018-04-26 Method of producing a pharmaceutical composition of disodium pemetrexed EA038700B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201800229A EA038700B1 (en) 2018-04-26 2018-04-26 Method of producing a pharmaceutical composition of disodium pemetrexed

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201800229A EA038700B1 (en) 2018-04-26 2018-04-26 Method of producing a pharmaceutical composition of disodium pemetrexed

Publications (2)

Publication Number Publication Date
EA201800229A1 true EA201800229A1 (en) 2019-10-31
EA038700B1 EA038700B1 (en) 2021-10-07

Family

ID=68319001

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201800229A EA038700B1 (en) 2018-04-26 2018-04-26 Method of producing a pharmaceutical composition of disodium pemetrexed

Country Status (1)

Country Link
EA (1) EA038700B1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102106833B (en) * 2011-02-12 2012-05-02 海南锦瑞制药股份有限公司 Pemetrexed disodium freeze-dried powder injection and preparation method thereof
CN103239415A (en) * 2012-05-18 2013-08-14 湖北一半天制药有限公司 Preparation method of pemetrexed disodium freeze-dried formulation for injection
CN103494777B (en) * 2013-08-23 2014-12-24 江苏奥赛康药业股份有限公司 Pemetrexed disodium freeze-dried composition and preparation method thereof

Also Published As

Publication number Publication date
EA038700B1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
CL2017001115A1 (en) Stable formulation of protein in solution that contains a high concentration of an anti-vegf antibody.
CL2018002920A1 (en) New pyrazolopyrimidine derivatives
DOP2019000110A (en) 1,2,4–2,4,5–TRI-SUBSTITUTED TRIAZOLONES
PH12020550051A1 (en) Glp-1 compositions and uses thereof
EA202191559A1 (en) MODIFIED AMINE LIPIDS
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA201891622A1 (en) NEW AMMONIUM DERIVATIVES, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA201790389A1 (en) PYRROPYRIMIDINE COMPOUNDS USED AS AN AGLIST TLR7
EA201892838A1 (en) NEW PIPERIDINILIC DERIVATIVES, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CL2019002511A1 (en) Pharmaceutical composition comprising selexipag.
BR112014009087A2 (en) xylitol stabilized etanercept formulations
CL2019002190A1 (en) Reduction of the viscosity of pharmaceutical formulations that comprise a therapeutic protein at a concentration of at least 70 mg / ml, where the therapeutic protein is not an antibody (divisional application 201700984)
MX2020007945A (en) Stabilized rsv f proteins and uses thereof.
CL2018003178A1 (en) Pharmaceutical composition
EA201691930A1 (en) SUBSTITUTED DERIVATIVES 4,5,6,7-TETRAHYDROPYRAZOLO [1,5-α] PYRAZINE AND DERIVATIVES 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO [1,5-α] [1,4] DIAZEPIN AS AN INHIBITORS ROS1
EA202090536A1 (en) CRYSTALLINE FORMS OF 3-SUBSTITUTED 1,2,4-OXADIAZOL
EA201991023A1 (en) PHARMACEUTICAL COMPOSITION FOR Parenteral Administration Containing Karglum Acid
MX2021004331A (en) Stable semaglutide compositions and uses thereof.
CY1117881T1 (en) SOLID PHARMACEUTICAL COMPOSITIONS INCLUDING BIOPTERINE PRODUCERS AND USES OF THESE COMPOSITIONS
MX2017009289A (en) Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same.
EA201890075A1 (en) INJECTABLE PHARMACEUTICAL COMPOSITIONS LEFAMULIN
EA201691807A1 (en) LYOPHILIZED COMPOSITIONS CONTAINING FACTOR IX
EA202191515A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING APIXABAN
EA201800229A1 (en) METHOD FOR PRODUCING PEMETREXEDA DISATRIUM 2,5-HYDRATE AND PHARMACEUTICAL COMPOSITION CONTAINING PEMETREXEDA DISATRIUM 2,5-HYDRATE
PH12019500024A1 (en) Pharmaceutical compositions